Delivery Order SPE2DB22D1017-SPE2DB25FG8RF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,233.41 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on July 31, 2025, with completion scheduled for August 1, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,525.16 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on July 30, 2025. This firm fixed-price delivery order, which is not set-aside, represents a small-value transaction under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,311.50 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order with an ultimate completion date of July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $20,902.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This contract, which carries an ultimate completion date of July 28, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order was competitively awarded without set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $44,409.63 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on July 30, 2025. This competitively awarded, firm fixed-price delivery order is not set-aside and represents a single transaction with a completion date of July 31, 2025. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections with a ceiling value of $1,586.80. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a diabetes and weight management medication,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,396.80 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.9 million through December 2026. The place of...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG8RFDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,138.12 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 31, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract calls for delivery to be completed by August 1, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The parent IDC vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support defense health programs. Zepbound, a GLP-1 receptor agonist indicated for weight management, represents one of numerous pharmaceutical products delivered through AmerisourceBergen's federal contracts, which span diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/31/25 |